Download - Bioprocess Eng
-
8/12/2019 Bioprocess Eng
1/28
Bioprocess for production of therapeutic agents
Manufacture of therapeutic agents : one of the most highlyregulated and rigorously controlled bioprocesses
To gain a manufacturing license, the producer proves that not onlythe product itself is safe and effective, but all aspects of the
proposed bioprocess comply with the highest safety and quality
standards
-
8/12/2019 Bioprocess Eng
2/28
Design and layout of the manufacturing facility Raw materials utilized in the process
Bioprocess itself
Training and commitment of personnel involved in all aspects
of the manufacturing operation
Existence of a regulatory framework which assures the
establishment and maintenance of the highest quality
standards regarding all aspects of bioprocess
Elements contributing to the safe production
-
8/12/2019 Bioprocess Eng
3/28
Overall manufacturing process
Infrastructure of a typical manufacturing facility
Source of therapeutic proteins
Up-stream and down-stream processing of products
Analysis of the final products : quality control
-
8/12/2019 Bioprocess Eng
4/28
Overall process
-
8/12/2019 Bioprocess Eng
5/28
Host cells for the production of biomolecules
Many of therapeutic agents currently on the market : produced
by recombinant DNA technology using various expressionsystems such as bacteria, yeast, fungi, and mammalian cells
Many therapeutic proteins are produced by recombinant DNA
technology
The use of appropriate expression system for specific products :
Each expression system displays its own unique set of
advantages and disadvantages
-
8/12/2019 Bioprocess Eng
6/28
E. coli
Most common microbial species used to produce heterologous proteins
- Heterologous protein : protein that does not occur in host cellsex) recombinant human insulin (Humulin) in 1982
tPA (tissue plasminogen activator in 1996
Major advantages of E. coli
- Its molecular biology is well characterized
- High level expression of heterologous proteins :
-High expression promoters
- ~ 30 % of total cellular protein
- Rapid growth, simple and inexpensive media, appropriate fermentationtechnology, large scale cultivation
-
8/12/2019 Bioprocess Eng
7/28
-
8/12/2019 Bioprocess Eng
8/28
Intracellular accumulation of proteins in the cytoplasm
complicate downstream processing compared to extracellular production
additional primary processing steps : cellular homogenization,
subsequent removal of cell debris by filtration or centrifugation
extensive purification steps to separate the protein of interest
Inclusion body (insoluble aggregates of partially folded protein)formation via intermolecular hydrophobic interactions
- high level expression of heterologous proteins overload the
normal cellular protein-folding mechanisms
- Nonetheless, inclusion body displays one processing advantage
easy and simple isolation by single step centrifugation
denaturation using 6 M urea
refolding via dialysis or diafiltration
Drawbacks of E. coli
-
8/12/2019 Bioprocess Eng
9/28
- Prevention of inclusion body formation- growth at lower temperature (30 oC)
- expression with fusion partner : GST, Thioredoxin, GFP,
- high level co-expression of molecular chaperones
Inability to undertake post-translational modification, especially glycosylation
: limitation to the production of glyco-proteins
Typical examples of glyco-proteins
Presence of lipopolysaccharide on its surface : pyrogenic nature
more complicate purification procedure
-
8/12/2019 Bioprocess Eng
10/28
Yeast
Saccharomyces cerevisiae, Pichia pastoris :
Major advantages
- Well-characterized molecular biologyeasy genetic manipulation
- Regarded as GRAS-listed organisms (generally regarded as safe)
Long history of industrial applications ( e.g., brewing and baking)
- Fast growth in relatively inexpensive media, outer cell wall
protects them from physical damage
- Suitable industrial scale fermentation equipment/technology is already available
- Post-translational modifications of proteins, especially glycosylation
-
8/12/2019 Bioprocess Eng
11/28
-
8/12/2019 Bioprocess Eng
12/28
Drawbacks
- Glycosylation pattern usually differs from the pattern observed in the
native glycoprotein : highly mannosylation pattern
-Low expression level of heterologous proteins : < 5 %
Many therapeutic proteins are produced in Yeast
-
8/12/2019 Bioprocess Eng
13/28
Fungal production system
Aspergillus niger
Mainly used for production of industrial enzymes : a-amylase, glucoamylase,
cellulase, lipase, protease etc..
Advantages
- High level expression of heterologous proteins
- Secretion of proteins into extracellular media
easy and simple separation procedure
- Post-translational modifications : glycosylation
- different glycostlation pattern compared to that in human
-
8/12/2019 Bioprocess Eng
14/28
-
8/12/2019 Bioprocess Eng
15/28
Animal cells
Major advantage : post-translational modifications, especially glycosylation
Chinese Hamster Ovary (CHO) and Baby Hamster Kidney (BHK) cells
Typical glycoproteins produced in animal cells
Drawbacks
- Complex nutritional requirements : growth factors
expensive
complicate the purification procedure
- Slow growth rate
- Far more susceptible to physical damage or contamination- Increased production costs
-
8/12/2019 Bioprocess Eng
16/28
CHO cells
-
8/12/2019 Bioprocess Eng
17/28
Transgenic animals
Transgenic animal : live bioreactor
Generation of transgenic animals : direct microinjection of exogenous DNA intoan egg cell
stable integration of the DNA into the genetic complement of the cell
after fertilization, the ova are implanted into a surrogate mother
the transgenic animal harbour a copy of the transferred DNA
In order for the transgenic animal system to be practically useful, the
recombinant protein must be easily separable from the animal
simple way is to produce a target protein in a mammary gland
simple recovery of a target protein from milk
-
8/12/2019 Bioprocess Eng
18/28
Mammary-specific expression : fusing the gene of interest with the promoter-
containing regulatory sequence of a gene coding for a milk-specific protein
ex) Regulatory sequences of the whey acid protein (WAP, the most abundant
protein in the milk), -casein, - and -lactoglobulin genes
ex) Production of tPA in the milk of transgenic mice
- Fusion of the tPA gene to the upstream regulatory sequence of
the mouse whey acidic protein
- More practical approach : production of tPA in the milk of
transgenic goats
Production of proteins in the milk of transgenic animals
-
8/12/2019 Bioprocess Eng
19/28
Goats and sheep : the most attractive host system
- high milk production capacities
- ease of handling and breeding
- ease of harvesting of crude product : simply requires
the animal to be milked
- pre-availability of commercial milking systems with
maximum process hygiene
- low capital investment : relatively low-cost animalsreplace high-cost traditional equipment and low running costs
- High expression levels of proteins are potentially attained :
> 1 g protein/liter milk
- on-going supply of product is guaranteed by breeding
- ease downstream processing due to well-characterized properties of major
native milk proteins
-
8/12/2019 Bioprocess Eng
20/28
Issues to be addressed for practical use
- variability of expression levels
- different post-translational modifications, especially glycosylation,
from that in human- significant time lag between the generation of a transgenic
embryo and commencement of routine product manufacture :
- gestation period ranging from 1 month to 9 months
- requires successful breeding before beginning to lactate
- the overall time lag : 3 years in the case of cows, 7 months in the case of
rabbits
- inefficient and time-consuming in the use of the micro-injection technique to
introduce the desired gene into the egg
-
8/12/2019 Bioprocess Eng
21/28
Another approaches
- Use of replication-defective retroviral vectors : consistent
delivery of a gene into cells and chromosomal integration
- Use of nuclear transfer technology
manipulation of donor cell nucleus so as to harbor a gene coding for a target
protein
substitution of genetic information in un unfertilized egg with donor genetic
information
transgenic sheep, Polly and Molly, producing human blood factor IX, in 1990s
-
8/12/2019 Bioprocess Eng
22/28
No therapeutic proteins produced in the milk of transgenic animals had
been approved for general medical use
Alternative approach : production of therapeutic proteins in the blood of
transgenic pigs and rabbits
- Drawbacks
- relatively low volumes of blood
- complicate downstream processing
- low stability of proteins in serum
-
8/12/2019 Bioprocess Eng
23/28
Transgenic plants
Expression of heterologous proteins in plant : introduction of foreign genes
into the plant species :Agrobacterium-based vector-mediated gene transfer
-Agarobacterium tumefaciens, A. rhizogenes ; soil-based plant
pathogens
- when infected, a proportion ofAgarobacteriumTi plasmid is
trans-located to the plant cell and is integrated into the plantcell genome
- Expression of therapeutic proteins in plant tissue
-
8/12/2019 Bioprocess Eng
24/28
Potentially attractive recombinant protein producer
- low cost of plant cultivation
- harvest equipment/methodologies are inexpensive and well established
- ease of scale-upProteins expressed in seeds are generally stably
- Plant-based systems are free of human pathogens(e.g., HIV)
Disadvantages- variable/low expression levels of proteins
- potential occurrence of post-translational gene silencing
( a sequence specific mRNA degradation mechanism)
- different glycosylation pattern from that in human
- seasonal/geographical nature of plant growth
-
8/12/2019 Bioprocess Eng
25/28
Most likely focus of future transgenic plant :
production of oral vaccines in edible plants or fruit, such as tomatoes an bananas
- ingestion of transgenic plant tissue expressing recombinant sub-unit vaccines
induces the production of antigen-specific antibody responses
direct consumption of plant material provides an inexpensive, efficient and
technically straightforward mode of large-scale vaccine delivery
Several hurdles
- the immunogenicity of orally administered vaccines vary widely
- the stability of antigens in the digestive tract varies widely
- genetics of many potential systems remain poorly characterized
inefficient transformation systems and low expression levels
I ll b d
-
8/12/2019 Bioprocess Eng
26/28
Insect cell-based system
Laboratory scale production of proteins
Infection of cultured insect cells with an engineered baculovirus
( a viral family that naturally infects insects) carrying the gene coding for a target
protein
Most commonly used systems- the silkworm virus Bombyx mori nuclear polyhedrovirus(BmNPV)
in conjunction with cultured silkworm cells
- the virusAutographa californica nuclear polyhedrovirus(AcNPV)
in conjunction with cultured armyworm cells
-
8/12/2019 Bioprocess Eng
27/28
Advantages
- High level intracellular protein expression
- The use of strong promoter derived from the viral polyhedrin :
~30-50 % of total intracellular protein- Cultivation at high growth rate and less expensive media than
animal cell lines
- no infection of human pathogens, e.g., HIV
Drawbacks
- low expression level of targeted extracellular production of protein
- glycosylation patterns : incomplete and different
No therapeutic protein approved for human use
-
8/12/2019 Bioprocess Eng
28/28
Alternative insect cell-based system
Use of live insects
- live caterpillars or silkworms
infection with the engineered baculovirus vector
Ex) Veterinary pharmaceutical company, Vibragen Owega
- The use of silkworm for the production of feline interferon